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October 12, 2010:1352–6THENA trial was designed to have only enough deaths to exclude
n important increase in mortality, which it did, with consistent
ndings across all important subgroups (6). In fact, the ATHENA
rial has more clearly demonstrated the safety of dronedarone than has
ver been previously achieved for any other antiarrhythmic drug.
ardiovascular death reduction is a very important finding that not
nly is consistent with the other benefits of dronedarone, but also was
of 3 secondary outcomes pre-specified. Should we discount this
nding because Singh et al. (1) are concerned that increased enroll-
ent from 4,300 to 4,600 patients might have been influenced by
nowledge of emerging trends in treatment effects, even though this
as a double-blind study? The protocol changes made during the
THENA trial were carried out without knowledge of any emerging
reatment effects and were performed to achieve the protocol-specified
oal of having 260 deaths, the required number pre-specified to
xclude an important increase in total mortality. The reduction in
ardiovascular hospitalization is clearly one of the pivotal findings of
he ATHENA trial. Should we, as Singh et al. (1) suggest, discount
his because events were not adjudicated by an external committee?
lthough adjudication would have increased the precision of the out-
ome, it would not have affected the validity of the observation that
ronedarone reduces cardiovascular hospitalization. This is because in-
estigators and patients were blinded to treatment, so there was virtually
o chance for bias. Although we have observed some variation in rates of
ardiovascular hospitalization between regions, the treatment effect of
ronedarone was highly consistent in all regions studied (9).
Should we be concerned that we still do not fully understand the
echanisms whereby dronedarone reduces cardiovascular hospitaliza-
ion and other vascular events? Some mechanisms are obvious—rate
nd rhythm effects slow heart rate and improve a variety of cardio-
ascular conditions, which are adversely affected by high rates. Blood
ressure-lowering and vasodilating and possible ventricular antiar-
hythmic effects may turn out to be important. Future studies will help
s to understand these effects.
The meta-analysis presented by Singh et al. (1) of 6 droneda-
one trials suffers from errors in methodology and accuracy, a few
f which are listed here:
. Inclusion of 1 trial of patients with heart failure (10) together
with 5 trials of patients with AF introduces needless heteroge-
neity, especially because dronedarone is indicated only for AF.
. The binomial approach does not take into account the censor-
ing process, whereas the most widely recommended approach
to summarize time-to-event data in clinical trials is the use of a
hazard ratio.
. The weighting of studies is not explained, nor does it even
reasonably reflect the patient-years of exposure of the studies,
vastly underweighting the ATHENA trial.
. Mean duration of follow-up in the ANDROMEDA (ANti-
arrhythmic trial with DROnedarone in Moderate to severe
congestive heart failure Evaluating morbidity DecreAse) trial is
incorrectly stated. It is 2 months, rather than 13 months (10).
In conclusion, the findings of the ATHENA trial are unique in
ntiarrhythmic drug therapy (6). For the first time, an antiarrhyth-
ic drug has been shown to have an important impact on
ardiovascular outcomes. Physicians no longer need to be satisfied
ith merely suppressing AF symptoms. Let us not miss the forest
or the trees, as Singh et al. (1) seems to have done. The
THENA results really do indicate a promising way forward tomproving patient outcomes through antiarrhythmic therapy. ttuart J. Connolly, MD
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eply
e appreciate the opportunity to clarify the issues raised by Drs.
onnolly and Hohnloser regarding our study (1). We agree that
ronedarone reduces first hospitalizations driven primarily by atrial
brillation in the ATHENA (A placebo-controlled, double-blind,
arallel arm Trial to assess the efficacy of dronedarone 400 mg bid
or the prevention of cardiovascular Hospitalization or death from
ny cause in patiENts with Atrial fibrillation/atrial flutter) trial (2),
ut reject the assertion that this makes it a major advance for the
reatment of atrial fibrillation. Although no other antiarrhythmic
rug has been shown to do this, it is entirely plausible that class I
r III antiarrhythmic drugs would have similar effects if systemat-
cally evaluated in this manner. This is precisely why comparative
ffectiveness research has become a cornerstone of evidence-based
edicine and health care reform. In this regard, it is surprising thathe ATHENA trial was not designed as an active control trial.
d
t
h
o
a
C
v
fi
a
t
t
o
o
t
f
d
4
f
d
H
5
N
t
i
t
I
d
s
i
o
M
c
v
d
s
t
n
c
r
o
s
c
s
p
b
t
(
c
t
A
M
D
d
c
d
b
m
s
a
D
E
G
*
*
C
8
L
E
R
1
2
3
4
T
M
I
T
t
m
i
a
p
s
b
s
l
c
t
m
p
o
t
o
w
r
a
r
i
1355JACC Vol. 56, No. 16, 2010 Correspondence
October 12, 2010:1352–6The validity of the observation that dronedarone reduces car-
iovascular hospitalization would have been strengthened if the
rial had documented systematically the underlying reasons for
ospitalizations (typically hemodynamic instability, exacerbation
f heart failure, anticoagulation, or cardioversion) and the expected
ttendant improvement in symptom status and quality of life.
oupled with the lack of external adjudication (that minimizes the
ulnerability to cardiovascular versus noncardiovascular misclassi-
cation errors, particularly in trials that span geographic regions
nd clinical practice settings) (3,4) and the exploratory nature of
he analysis (given the pre-specified hierarchical sequential plan),
hese limitations serve not only to undermine the clinical relevance
f this finding, but also to raise questions about the overall quality
f the data, and ultimately the reliability of the findings.
The original report mentions 1 amendment dated March 8, 2006,
o alter the enrollment criterion to include older subjects (2). No
urther protocol changes are mentioned, including the amendment
ated August 25, 2006, to increase the sample size from 3,700 to
,300, nor is any reason given for the extension of the sample size
rom 4,300 to 4,628. We do not doubt these protocol changes were
one blindly, without knowledge of any emerging treatment effects.
owever, we are intrigued that investigators stopped at 255 deaths,
short of achieving the protocol-specified goal of 260 deaths.
onetheless, these protocol changes should have been reported in a
ransparent manner and appropriate caution should have been urged
n interpreting cardiovascular death results as being exploratory, given
he rules of engagement of a hierarchical sequential analysis plan.
nstead, the published conclusion that the drug reduced cardiovascular
eaths is highly misleading, when in reality that benefit was not
ignificant under the original plan (1). Although no malfeasance is
mplied, we nonetheless feel strongly that changing rules in the middle
f the trial is antithetical to the principles of good clinical trial practice.
oreover, the mechanisms that underlie dronedarone’s reduction of
ardiovascular death remain unclear. Death resulting from stroke,
entricular arrhythmia, or heart failure was not impacted favorably by
ronedarone (2). Did the associated reductions in acute coronary
yndromes—a post-hoc observation—account for this finding, or was
his merely the play of chance? In the end, the ATHENA trial was
ot designed to answer these questions, and the observed reduction in
ardiovascular death is at best exploratory and hypothesis generating,
equiring confirmation in subsequent studies.
The authors have raised issues with our meta-analysis. The
bjective was not solely to estimate an overall measure of effect (a
ynthesis-centric goal), where it is appropriate to question whether
ertain studies should be combined, but rather to explore the rea-
ons for differences between the studies (an analysis-centric goal) to
lace the evidence in its proper context. The results are insightful
ecause they provide reassurance about dronedarone’s safety in the
arget population (1). The weighting is described in the figure legend
1), and adjusting for patient-years of exposure did not materially
hange the summary relative risk estimate. Finally, we acknowledge
he typographical error regarding the mean follow-up in the
NDROMEDA (ANti-arrhythmic trial with DROnedarone in
oderate to severe congestive heart failure Evaluating morbidity
ecreAse) trial, which had no impact on our analysis.
Rather than missing the forest for the trees, we present the evi-
ence in an objective and unembellished manner. Although the truth
an be determined by each reader, the plain fact, in our opinion, is that
ronedarone has very modest efficacy as an antiarrhythmic agent, and
ased on the current evidence, its use for the treatment of nonper-
anent atrial fibrillation or atrial flutter can be supported only as a recond- or third-line agent in individuals who are not able to tolerate
miodarone or other first-line agents recommended by the guidelines.
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he Concept of the
etabolic Syndrome
s It Dead Yet?
he main finding of the case-control study by Mente et al. (1) is that
he risk of myocardial infarction associated with the diagnosis of
etabolic syndrome (MS) is no greater than that of the sum of its
ndividual components. However, this interpretation is solely based on
finding of similar effect sizes (odds ratio) associated with MS and
reviously diagnosed (and/or treated) diabetes mellitus or hyperten-
ion. The authors note that, in this study (as in many other studies),
oth hypertension and diabetes frequently coexisted. Moreover, they
uggest that the patients with hypertension or diabetes were more
ikely to have at least 1 additional component of MS present (most
ommonly, central obesity: 71%). Therefore, it is not surprising that
he odds ratio associated with each of them in separate regression
odels was found to be similar to that obtained by the use of MS, as
atients with both diabetes and hypertension also had clustering of
ther individual components. We believe it would be more informa-
ive to describe the effect sizes associated with those with only diabetes
r only hypertension, when comparing them with those associated
ith the presence of MS. However, to assess whether the sum of the
isk associated with individual components is greater than that
ssociated with the presence of MS, it may be better to estimate the
isk of myocardial infarction associated with MS, after adjusting for all
ts individual components (when used as continuous variables) in a
egression model.
